J&J Expands Ketamine Case With Spravato Monotherapy Indication

On the US market since 2019 for treatment-resistant depression in tandem with oral antidepressants, J&J’s new indication allows for more flexibility.

J&J obtained a third US indication for treatment-resistant depression drug Spravato • Source: Scrip

More from Business

More from Therapy Areas